Welcome to our dedicated page for JOCOM HOLDINGS SEC filings (Ticker: JOCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on JOCOM HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into JOCOM HOLDINGS's regulatory disclosures and financial reporting.
JOCOM Holdings Corp. reported a broad leadership transition effective August 6, 2026. At 12:00 p.m., Loke Weng Chan resigned as President, Secretary, Treasurer, Managing Director, and Director, and Dr. Jimmy Loke resigned as Chief Executive Officer and Chief Financial Officer; both departures are stated as not due to any disagreement over operations, policies, or practices.
Effective 12:01 p.m. the same day, Chai Kok Leong (age 60) became President, Chief Executive Officer, and Director; Gilbert Loke Che Chan (age 71) became Chief Financial Officer, Treasurer, Chairman, and Director; Tang Shung Ching Louis (age 60) became Chief Marketing Officer and Director; and Zheng Xiang (age 38) became Chief Technical Officer and Director. Dr. Jimmy Loke (Loke Yu), age 77, moved to the role of Chief Strategy Officer.
The company notes that Gilbert Loke is the brother of Chief Strategy Officer Dr. Jimmy Loke. It states there are no other disclosable family relationships, no related-party transactions requiring disclosure, and no appointing arrangements beyond those described. Compensation terms for the newly appointed executives and directors have not yet been determined and will be disclosed in accordance with applicable SEC requirements.
JOCOM HOLDINGS CORP. notifies the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company states it needs additional time to compile and analyze supporting documentation and to permit its independent registered public accounting firm to complete its review of the condensed consolidated financial statements.
The notification is made under Rule 12b-25 and seeks relief to file the Form 10-Q within the permitted extension period.
Jocom Holdings Corp. reports a sharp downturn for the year ended December 31, 2025, moving from a small profit to a net loss of $839,842. Revenue fell to $0 from $24,000 as the company shifted direction and impaired receivables and deposits of $648,000.
Other income of $97,378, including a $67,987 liability waiver, was not enough to offset a jump in general and administrative expenses to $937,220. Operating cash outflow reached $491,306, while a common stock issuance brought in net financing cash of $500,000.
Jocom ended 2025 with only $11,220 in cash, total assets of $15,840, current liabilities of $122,080 and a stockholders’ deficit of $106,240. Auditors raised substantial doubt about the company’s ability to continue as a going concern. The company has 65,680,500 common shares outstanding and its stock is quoted on the OTCQB under symbol JOCM.
Jocom Holdings Corp. notified the SEC that it is unable to file its Annual Report on Form 10-K for the period ended December 31, 2025. The company says it needs additional time to compile and analyze supporting documentation and to permit its independent registered public accounting firm to complete its audit.
Jocom Holdings Corp. (JOCM) filed its Q3 2025 10‑Q reporting a net loss and a going concern warning. The company posted a net loss of $126,819 for the nine months ended September 30, 2025, versus net profit of $37,218 a year ago, driven by general and administrative expenses of $213,914 (up from $80,165) and $0 revenue (vs. $18,000). Other income was $87,095.
Operating cash outflow was $479,644, partly offset by $500,000 net cash from financing after $800,000 of unregistered common stock sales at $0.10 per share, with a $300,000 subscription receivable outstanding. Cash ended at $22,987. The company recorded $348,000 in deposits as earnest money toward acquiring Yijun (Shanghai) Biotechnology Co. Ltd., stated as expected to complete by Q2 2026. 65,680,500 shares were outstanding as of September 30, 2025, and stockholders’ equity improved to $306,769.
Management disclosed material weaknesses in internal controls and stated that recurring losses, accumulated deficit, and negative operating cash flows raise substantial doubt about continuing as a going concern.